PD05 Safety Profile Of Miltefosine In The Treatment Of Cutaneous Leishmaniasis: An Analysis Of Use In Minas Gerais, Brazil
Sarah Silva, Laís Ribeiro, Janaína Carvalho, Mell Saliba, Gláucia Cota · 2025
Read PD05 Safety Profile Of Miltefosine In The Treatment Of Cutaneous Leishmaniasis: An Analysis Of Use In Minas Gerais, Brazil by Sarah Silva, Laís Ribeiro, Janaína Carvalho, Mell Saliba, Gláucia Cota (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12768681.txt.
Description
Sarah Silva and co-authors track the safety of a leishmaniasis drug as Brazil rolled it out, in a 2025 conference report. Miltefosine treats the skin form of the disease, and new drugs entering a public system need close watching in their first years.
The team analyzed every patient treated in Minas Gerais state between May 2021 and July 2023, using the official reporting and monitoring forms. About seventy-seven percent of patients had some side effect, mostly stomach complaints. Severe events were uncommon, though six patients needed hospital care. Events were graded by standard world criteria for type and strength. The profile tells clinics what to expect and counsel as the drug spreads.
Catalog record
| CREATOR | Sarah Silva, Laís Ribeiro, Janaína Carvalho, Mell Saliba, Gláucia Cota |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 2 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |